Cytokinetics and Novartis’ starcrossed tale

If you are interested in staying up to date on the latest developments in the biotech industry, you can sign up for the STAT biotech newsletter in your inbox. This week’s newsletter includes topics such as the aftermath of the JPM conference, FDA review of GLP-1 drugs, Novartis’ decision not to acquire Cytokinetics, and a study revealing that contributors to the DSM-5 received $14 million from industry. The newsletter is taking a break on Monday in observance of Martin Luther King Jr. Day, and will return on Tuesday. The content also includes a link to a biotech podcast and further reading on these topics.

Source link

error: Content is protected !!